Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

KRMD vs INFU vs AVNS vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
KRMD
KORU Medical Systems, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$207M
5Y Perf.-56.1%
INFU
InfuSystem Holdings, Inc.

Medical - Instruments & Supplies

HealthcareAMEX • US
Market Cap$181M
5Y Perf.-22.8%
AVNS
Avanos Medical, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.16B
5Y Perf.-14.8%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$55.53B
5Y Perf.+3.0%

KRMD vs INFU vs AVNS vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
KRMD logoKRMD
INFU logoINFU
AVNS logoAVNS
BDX logoBDX
IndustryMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & Supplies
Market Cap$207M$181M$1.16B$55.53B
Revenue (TTM)$43M$142M$716M$21.36B
Net Income (TTM)$-2M$8M$-69M$1.14B
Gross Margin60.1%56.7%49.4%46.5%
Operating Margin-5.1%9.1%-8.4%10.6%
Forward P/E21.5x24.8x12.3x
Total Debt$3M$3M$129M$19.18B
Cash & Equiv.$9M$3M$90M$851M

KRMD vs INFU vs AVNS vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

KRMD
INFU
AVNS
BDX
StockMay 20May 26Return
KORU Medical System… (KRMD)10043.9-56.1%
InfuSystem Holdings… (INFU)10077.2-22.8%
Avanos Medical, Inc. (AVNS)10085.2-14.8%
Becton, Dickinson a… (BDX)100103.0+3.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: KRMD vs INFU vs AVNS vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BDX leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. InfuSystem Holdings, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. KRMD and AVNS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
KRMD
KORU Medical Systems, Inc.
The Growth Play

KRMD is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 22.2%, EPS growth 56.1%, 3Y rev CAGR 13.8%
  • 11.2% 10Y total return vs BDX's 80.2%
  • Lower volatility, beta 1.15, Low D/E 20.5%, current ratio 2.44x
  • Beta 1.15, current ratio 2.44x
Best for: growth exposure and long-term compounding
INFU
InfuSystem Holdings, Inc.
The Quality Compounder

INFU is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 5.6% margin vs AVNS's -9.7%
  • 7.9% ROA vs KRMD's -8.3%, ROIC 12.5% vs -19.5%
Best for: quality and efficiency
AVNS
Avanos Medical, Inc.
The Momentum Pick

AVNS is the clearest fit if your priority is momentum.

  • +96.9% vs BDX's +51.8%
Best for: momentum
BDX
Becton, Dickinson and Company
The Income Pick

BDX carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 1 yrs, beta 0.66, yield 2.7%
  • Lower P/E (12.3x vs 24.8x)
  • Beta 0.66 vs AVNS's 1.54
  • 2.7% yield; 1-year raise streak; the other 3 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthKRMD logoKRMD22.2% revenue growth vs AVNS's 1.9%
ValueBDX logoBDXLower P/E (12.3x vs 24.8x)
Quality / MarginsINFU logoINFU5.6% margin vs AVNS's -9.7%
Stability / SafetyBDX logoBDXBeta 0.66 vs AVNS's 1.54
DividendsBDX logoBDX2.7% yield; 1-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)AVNS logoAVNS+96.9% vs BDX's +51.8%
Efficiency (ROA)INFU logoINFU7.9% ROA vs KRMD's -8.3%, ROIC 12.5% vs -19.5%

KRMD vs INFU vs AVNS vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

KRMDKORU Medical Systems, Inc.

Segment breakdown not available.

INFUInfuSystem Holdings, Inc.
FY 2025
Patient Services
57.4%$87M
Device Solutions
42.6%$64M
AVNSAvanos Medical, Inc.
FY 2025
Corporate Other
100.0%$31M
BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

KRMD vs INFU vs AVNS vs BDX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINFULAGGINGBDX

Income & Cash Flow (Last 12 Months)

INFU leads this category, winning 3 of 6 comparable metrics.

BDX is the larger business by revenue, generating $21.4B annually — 493.9x KRMD's $43M. INFU is the more profitable business, keeping 5.6% of every revenue dollar as net income compared to AVNS's -9.7%. On growth, KRMD holds the edge at +22.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricKRMD logoKRMDKORU Medical Syst…INFU logoINFUInfuSystem Holdin…AVNS logoAVNSAvanos Medical, I…BDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$43M$142M$716M$21.4B
EBITDAEarnings before interest/tax-$1M$23M-$21M$4.2B
Net IncomeAfter-tax profit-$2M$8M-$69M$1.1B
Free Cash FlowCash after capex$179,290$22M$24M$3.1B
Gross MarginGross profit ÷ Revenue+60.1%+56.7%+49.4%+46.5%
Operating MarginEBIT ÷ Revenue-5.1%+9.1%-8.4%+10.6%
Net MarginNet income ÷ Revenue-5.3%+5.6%-9.7%+5.3%
FCF MarginFCF ÷ Revenue+0.4%+15.4%+3.4%+14.7%
Rev. Growth (YoY)Latest quarter vs prior year+22.1%-3.0%+8.8%-10.6%
EPS Growth (YoY)Latest quarter vs prior year+33.3%+6.0%-21.4%-2.0%
INFU leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

INFU leads this category, winning 3 of 6 comparable metrics.

At 26.3x trailing earnings, BDX trades at a 9% valuation discount to INFU's 28.9x P/E. On an enterprise value basis, INFU's 7.2x EV/EBITDA is more attractive than BDX's 14.7x.

MetricKRMD logoKRMDKORU Medical Syst…INFU logoINFUInfuSystem Holdin…AVNS logoAVNSAvanos Medical, I…BDX logoBDXBecton, Dickinson…
Market CapShares × price$207M$181M$1.2B$55.5B
Enterprise ValueMkt cap + debt − cash$201M$181M$1.2B$73.9B
Trailing P/EPrice ÷ TTM EPS-77.76x28.90x-16.97x26.29x
Forward P/EPrice ÷ next-FY EPS est.21.54x24.77x12.27x
PEG RatioP/E ÷ EPS growth rate1.59x
EV / EBITDAEnterprise value multiple7.19x14.65x
Price / SalesMarket cap ÷ Revenue5.02x1.26x1.65x2.54x
Price / BookPrice ÷ Book value/share12.03x3.30x1.48x1.73x
Price / FCFMarket cap ÷ FCF7.59x26.91x20.80x
INFU leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

INFU leads this category, winning 8 of 9 comparable metrics.

INFU delivers a 14.0% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-14 for KRMD. INFU carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to BDX's 0.76x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs AVNS's 5/9, reflecting strong financial health.

MetricKRMD logoKRMDKORU Medical Syst…INFU logoINFUInfuSystem Holdin…AVNS logoAVNSAvanos Medical, I…BDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity-13.6%+14.0%-8.9%+4.5%
ROA (TTM)Return on assets-8.3%+7.9%-6.6%+2.1%
ROICReturn on invested capital-19.5%+12.5%-5.4%+4.3%
ROCEReturn on capital employed-14.9%+14.3%-6.5%+5.4%
Piotroski ScoreFundamental quality 0–95857
Debt / EquityFinancial leverage0.21x0.06x0.17x0.76x
Net DebtTotal debt minus cash-$5M$241,000$39M$18.3B
Cash & Equiv.Liquid assets$9M$3M$90M$851M
Total DebtShort + long-term debt$3M$3M$129M$19.2B
Interest CoverageEBIT ÷ Interest expense13.65x-16.71x4.09x
INFU leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KRMD leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in KRMD five years ago would be worth $12,402 today (with dividends reinvested), compared to $4,297 for INFU. Over the past 12 months, AVNS leads with a +96.9% total return vs BDX's +51.8%. The 3-year compound annual growth rate (CAGR) favors KRMD at 4.2% vs INFU's 0.9% — a key indicator of consistent wealth creation.

MetricKRMD logoKRMDKORU Medical Syst…INFU logoINFUInfuSystem Holdin…AVNS logoAVNSAvanos Medical, I…BDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date-20.9%+6.8%+121.6%+0.7%
1-Year ReturnPast 12 months+63.2%+88.6%+96.9%+51.8%
3-Year ReturnCumulative with dividends+13.3%+2.8%+5.6%+5.0%
5-Year ReturnCumulative with dividends+24.0%-57.0%-39.8%+16.9%
10-Year ReturnCumulative with dividends+1116.4%+159.0%-17.0%+80.2%
CAGR (3Y)Annualised 3-year return+4.2%+0.9%+1.8%+1.6%
KRMD leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AVNS and BDX each lead in 1 of 2 comparable metrics.

BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than AVNS's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVNS currently trades 99.9% from its 52-week high vs KRMD's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricKRMD logoKRMDKORU Medical Syst…INFU logoINFUInfuSystem Holdin…AVNS logoAVNSAvanos Medical, I…BDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5001.15x1.50x1.54x0.66x
52-Week HighHighest price in past year$6.61$11.04$24.80$205.52
52-Week LowLowest price in past year$2.63$4.70$9.30$100.31
% of 52W HighCurrent price vs 52-week peak+67.2%+81.2%+99.9%+74.6%
RSI (14)Momentum oscillator 0–10042.951.590.832.2
Avg Volume (50D)Average daily shares traded138K121K1.3M2.5M
Evenly matched — AVNS and BDX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — AVNS and BDX each lead in 1 of 1 comparable metric.

Analyst consensus: KRMD as "Buy", INFU as "Buy", AVNS as "Hold", BDX as "Buy". Consensus price targets imply 67.4% upside for INFU (target: $15) vs -7.1% for AVNS (target: $23). BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.

MetricKRMD logoKRMDKORU Medical Syst…INFU logoINFUInfuSystem Holdin…AVNS logoAVNSAvanos Medical, I…BDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$7.00$15.00$23.00$172.85
# AnalystsCovering analysts53833
Dividend YieldAnnual dividend ÷ price+2.7%
Dividend StreakConsecutive years of raises011
Dividend / ShareAnnual DPS$4.17
Buyback YieldShare repurchases ÷ mkt cap0.0%+6.1%+0.3%+1.8%
Evenly matched — AVNS and BDX each lead in 1 of 1 comparable metric.
Key Takeaway

INFU leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). KRMD leads in 1 (Total Returns). 2 tied.

Best OverallInfuSystem Holdings, Inc. (INFU)Leads 3 of 6 categories
Loading custom metrics...

KRMD vs INFU vs AVNS vs BDX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is KRMD or INFU or AVNS or BDX a better buy right now?

For growth investors, KORU Medical Systems, Inc.

(KRMD) is the stronger pick with 22. 2% revenue growth year-over-year, versus 1. 9% for Avanos Medical, Inc. (AVNS). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate KORU Medical Systems, Inc. (KRMD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — KRMD or INFU or AVNS or BDX?

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.

3x versus InfuSystem Holdings, Inc. at 28. 9x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 12. 3x.

03

Which is the better long-term investment — KRMD or INFU or AVNS or BDX?

Over the past 5 years, KORU Medical Systems, Inc.

(KRMD) delivered a total return of +24. 0%, compared to -57. 0% for InfuSystem Holdings, Inc. (INFU). Over 10 years, the gap is even starker: KRMD returned +1116% versus AVNS's -17. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — KRMD or INFU or AVNS or BDX?

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Avanos Medical, Inc. 's 1. 54β — meaning AVNS is approximately 135% more volatile than BDX relative to the S&P 500. On balance sheet safety, InfuSystem Holdings, Inc. (INFU) carries a lower debt/equity ratio of 6% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — KRMD or INFU or AVNS or BDX?

By revenue growth (latest reported year), KORU Medical Systems, Inc.

(KRMD) is pulling ahead at 22. 2% versus 1. 9% for Avanos Medical, Inc. (AVNS). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, KRMD leads at 13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — KRMD or INFU or AVNS or BDX?

Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.

7% net margin versus -9. 7% for Avanos Medical, Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -8. 8% for AVNS. At the gross margin level — before operating expenses — KRMD leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is KRMD or INFU or AVNS or BDX more undervalued right now?

On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12.

3x forward P/E versus 24. 8x for Avanos Medical, Inc. — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INFU: 67. 4% to $15. 00.

08

Which pays a better dividend — KRMD or INFU or AVNS or BDX?

In this comparison, BDX (2.

7% yield) pays a dividend. KRMD, INFU, AVNS do not pay a meaningful dividend and should not be held primarily for income.

09

Is KRMD or INFU or AVNS or BDX better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Avanos Medical, Inc. (AVNS) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +80. 2%, AVNS: -17. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between KRMD and INFU and AVNS and BDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KRMD is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; AVNS is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while KRMD, INFU, AVNS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

KRMD

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 36%
Run This Screen
Stocks Like

INFU

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

AVNS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 29%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.0%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform KRMD and INFU and AVNS and BDX on the metrics below

Revenue Growth>
%
(KRMD: 22.1% · INFU: -3.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.